B. Riley Adjusts Price Target on MiNK Therapeutics to $50 From $43, Maintains Buy Rating

Article summary

B. Riley has increased its price target for MiNK Therapeutics, Inc. from $43 to $50 while maintaining a 'Buy' rating on the stock.